Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States

BACKGROUND: Biologics are an important treatment option for solid tumors and hematological malignancies but are a primary driver of health care spending growth. The United States has yet to realize the promise of reduced costs via biosimilars because of slow uptake, partially resulting from commerci...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jingyan, Carioto, Jennifer, Pyenson, Bruce, Smith, Rebecca, Jacobson, Nathaniel, Pittinger, Sean, Shelbaya, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394213/
https://www.ncbi.nlm.nih.gov/pubmed/34677089
http://dx.doi.org/10.18553/jmcp.2021.21202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394213/
https://www.ncbi.nlm.nih.gov/pubmed/34677089
http://dx.doi.org/10.18553/jmcp.2021.21202

Ejemplares similares